Merck Reports 4% Sales Increase to $17.3 Billion in Q3 2025

Merck & Co., Inc. reported a notable increase in its financial performance for the third quarter of 2025, with total sales reaching $17.3 billion, a 4% rise compared to $16.7 billion in the same period last year. The company's net income attributable to Merck increased significantly to $5.8 billion, or $2.32 per share, from $3.2 billion, or $1.25 per share, in the prior year. For the first nine months of 2025, total sales were $48.6 billion, slightly up from $48.5 billion in 2024, while net income rose to $15.3 billion from $13.4 billion.

The company experienced a 15% increase in U.S. sales, driven primarily by its oncology products, particularly Keytruda, which saw sales of $8.1 billion, up from $7.4 billion. However, international sales declined by 8%, attributed to lower demand in several markets, including China and Japan. Merck's restructuring efforts, which included a new program aimed at optimizing its operations, resulted in restructuring costs of $676 million for the first nine months of 2025, compared to $258 million in the same period of 2024.

Strategically, Merck made significant moves in its business development, including the acquisition of Verona Pharma for approximately $10.5 billion, which enhances its respiratory disease portfolio with the addition of Ohtuvayre, a treatment for chronic obstructive pulmonary disease (COPD). Additionally, Merck entered into a funding arrangement with Blackstone Life Sciences, securing $700 million to support the development of MK-2870, an investigational cancer treatment. The company also discontinued a co-development agreement with Dr. Falk Pharma, assuming full responsibility for the MK-8690 development program.

Operationally, Merck's workforce remains stable, with a total employee count of approximately 70,000 as of September 30, 2025. The company continues to focus on expanding its geographic reach and product adoption rates, particularly in oncology and animal health. The company anticipates that its restructuring initiatives will yield annual cost savings of approximately $1.7 billion by the end of 2027, which will be reinvested into strategic growth areas.

Looking ahead, Merck's management expressed optimism about future growth, despite ongoing challenges such as pricing pressures from government regulations and competition. The company expects to continue leveraging its strong product pipeline and strategic acquisitions to drive performance. The effective tax rate for the third quarter of 2025 was reported at 14.2%, reflecting a favorable geographical mix of income and certain discrete items.